A Randomized, Double Blind, Placebo Controlled Trial of Immunotherapy With Autologous Antigen-Loaded Dendritic Cells (Provenge®, APC8015) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer.

Trial Profile

A Randomized, Double Blind, Placebo Controlled Trial of Immunotherapy With Autologous Antigen-Loaded Dendritic Cells (Provenge®, APC8015) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Feb 2017

At a glance

  • Drugs Sipuleucel-T (Primary)
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Dendreon Corporation
  • Most Recent Events

    • 18 Feb 2017 Results of survival outcomes from three phase III studies including this study presented at the 2017 Genitourinary Cancers Symposium
    • 17 Sep 2013 Sipuleucel-T has been approved by the European Commission for the treatment of asymptomatic or minimally symptomatic, metastatic hormone-refractory prostate cancer. Approval was based on the results of this and 2 other trials.
    • 16 May 2012 Results from an exploratory analysis will be presented at the 48th Annual Meeting of the American Society of Clinical Oncology, according to a Dendreon Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top